Caris Life Sciences Inc (CAI)

Currency in USD
23.20
-0.12(-0.51%)
Closed·
23.200.00(0.00%)
·
Trading near 52-week Low
CAI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
22.5523.99
52 wk Range
22.5542.50
Key Statistics
Prev. Close
23.32
Open
23.41
Day's Range
22.55-23.99
52 wk Range
22.55-42.5
Volume
2.7M
Average Volume (3m)
2.34M
1-Year Change
-
Book Value / Share
1.7
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CAI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
37.89
Upside
+63.31%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Caris Life Sciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Caris Life Sciences Inc Company Profile

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company’s molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company has a partnership with Everly Health, Inc. for the development of Caris Detect, a Multi-Cancer Early Detection (MCED) blood-based screening assay. The company was founded in 2008 and is headquartered in Irving, Texas.

Compare CAI to Peers and Sector

Metrics to compare
CAI
Peers
Sector
Relationship
P/E Ratio
−9.6x−4.3x−0.6x
PEG Ratio
-−0.030.00
Price/Book
13.8x5.6x2.6x
Price / LTM Sales
10.1x9.5x3.3x
Upside (Analyst Target)
63.0%36.9%44.6%
Fair Value Upside
Unlock9.4%6.0%Unlock

Analyst Ratings

8 Buy
1 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 37.89
(+63.31% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Canaccord Genuity
Hold30.00+29.31%-MaintainJan 26, 2026
Canaccord Genuity
Hold30.00+29.31%-MaintainJan 13, 2026
Canaccord Genuity
Buy30.00+29.31%28.00MaintainDec 22, 2025
Canaccord Genuity
Hold28.00+20.69%-New CoverageDec 02, 2025
TD Cowen
Buy38.00+63.79%32.00MaintainAug 13, 2025

Earnings

Latest Release
Nov 05, 2025
EPS / Forecast
0.08 / --
Revenue / Forecast
216.80M / --
EPS Revisions
Last 90 days

CAI Income Statement

People Also Watch

10.34
NAVN
-4.17%
18.96
DYN
+1.07%
49.96
CRNX
+1.24%
55.73
PCVX
-2.91%
16.79
NRIX
-1.76%

FAQ

What Is the Caris Life Sciences (CAI) Stock Price Today?

The Caris Life Sciences stock price today is 23.20

What Stock Exchange Does Caris Life Sciences Trade On?

Caris Life Sciences is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Caris Life Sciences?

The stock symbol for Caris Life Sciences is "CAI."

What Is the Caris Life Sciences Market Cap?

As of today, Caris Life Sciences market cap is 6.58B.

What Is Caris Life Sciences's Earnings Per Share (TTM)?

The Caris Life Sciences EPS (TTM) is -6.48.

When Is the Next Caris Life Sciences Earnings Date?

Caris Life Sciences will release its next earnings report on Feb 25, 2026.

From a Technical Analysis Perspective, Is CAI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Caris Life Sciences Stock Split?

Caris Life Sciences has split 0 times.

How Many Employees Does Caris Life Sciences Have?

Caris Life Sciences has 1769 employees.

What is the current trading status of Caris Life Sciences (CAI)?

As of Feb 04, 2026, Caris Life Sciences (CAI) is trading at a price of 23.20, with a previous close of 23.32. The stock has fluctuated within a day range of 22.55 to 23.99, while its 52-week range spans from 22.55 to 42.50.

What Is Caris Life Sciences (CAI) Price Target According to Analysts?

The average 12-month price target for Caris Life Sciences is USD37.89, with a high estimate of USD45 and a low estimate of USD30. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +63.31% Upside potential.

What Is the CAI Premarket Price?

CAI's last pre-market stock price is 23.17. The pre-market share volume is 780.00, and the stock has decreased by -0.15, or -0.64%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.